Overview

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Status:
Not yet recruiting

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

HS-10241, an oral and highly selective MET-TKI, may contribute to overcoming common acquired MET-based resistance mechanisms following prior EGFR-TKI monotherapy. This study is conducted to evaluate the efficacy and safety of HS-10241 combined with Almonertinib versus platinum-based chemotherapy in NSCLC with MET amplification after failure of EGFR-TKI treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Treatments:

Carboplatin
Pemetrexed